Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride use was significantly associated with the reporting of obstructive sleep apnea and insomnia compared to all other drugs in the FAERS database.

Oral minoxidil helps female hair loss, topical finasteride treats AGA, and sulfotransferase activity predicts minoxidil effectiveness.

This study found that finasteride use was significantly associated with reports of obstructive sleep apnea and insomnia compared to other drugs in the FAERS database.

In this study, the authors reported no significant difference in sexual dysfunction between finasteride users and non-users among men with androgenetic alopecia, suggesting that finasteride does not cause sexual dysfunction. This finding aligns with other large survey-based studies.

This review discusses bio-based polymers, highlighting their potential in wound healing applications, but reports no new clinical results.

This study found that desmocollin 1 is crucial for strong adhesion and barrier maintenance in the mouse epidermis, with its absence leading to skin and hair issues resembling chronic dermatitis.

Male pattern hair loss could hint at androgens affecting COVID-19 severity.

This article argues that androgen sensitivity could be a key factor in the severity of COVID-19, suggesting that trials with anti-androgen agents may be warranted.

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.

This study found that the Dun camouflage color in horses is due to TBX3 expression, which causes uneven pigment deposition, whereas non-dun coat colors result from regulatory mutations affecting TBX3 expression.

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

This letter discusses the potential connection between androgenetic alopecia and COVID-19, suggesting a possible new therapy, but it reports no new results.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

Spironolactone might help protect against severe lung problems in COVID-19 patients.

This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.

This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.

This article is a discussion piece that examines the clinical symptoms of hyperandrogenic women with COVID-19, without reporting new research findings.

This publication is a letter discussing the association between an androgen receptor genetic variant and COVID-19 disease severity in hospitalized male patients, but it reports no new research results.

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.

In this study, ustekinumab did not promote hair regrowth in human patients with alopecia areata or prevent disease development in an AA mouse model, suggesting limited efficacy for this treatment.

This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.

This review summarizes the promising role of melatonin combined with nanosized carriers in drug delivery, suggesting enhanced effectiveness in treating various diseases compared to free melatonin.

In this study, early treatment with nitazoxanide, ivermectin, or hydroxychloroquine, combined with azithromycin, was associated with reduced hospitalizations, respiratory complications, and deaths in early-stage COVID-19 patients compared to untreated controls.